Homology Medicines Inc - SIC # 5912 - DRUG STORES AND PROPRIETARY STORES

Ticker Exchange SIC # Website Latest Ticker
FIXX Nasdaq 5912 https://www.homologymedicines.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Homology Medicines Inc

Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting - Mar 15th, 2023 8:01 pm
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates - Mar 9th, 2023 11:45 pm
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights - Mar 9th, 2023 9:05 pm
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer - Mar 9th, 2023 1:00 pm
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference - Mar 2nd, 2023 12:30 pm
Homology Medicines (NASDAQ:FIXX) shareholders have endured a 90% loss from investing in the stock three years ago - Feb 24th, 2023 10:31 am
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting - Feb 22nd, 2023 9:01 pm
Homology Medicines Provides Update From Gene Therapy Trials - Jan 5th, 2023 2:25 pm
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs - Jan 4th, 2023 9:01 pm
Homology Medicines Third Quarter 2022 Earnings: Misses Expectations - Nov 12th, 2022 1:08 pm
Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2022 10:45 pm
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights - Nov 10th, 2022 9:07 pm
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting - Oct 27th, 2022 1:00 pm
Homology Medicines to Participate at Upcoming Conferences - Oct 6th, 2022 12:30 pm
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures - Sep 27th, 2022 12:15 pm
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer - Sep 6th, 2022 8:01 pm
Homology Medicines Pauses Enrollment For Rare Inherited Disorder Study - Aug 16th, 2022 3:52 pm
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates - Aug 15th, 2022 10:15 pm
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update - Aug 15th, 2022 8:10 pm
Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder - Aug 12th, 2022 11:46 am